EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vaccinating against infiltrative glioma: antigen selection, neuronal niches, and immune access

Hiroyuki Tomita, Akira Hara

Frontiers in Immunology · 19.11.2026 · 17

DOI: 10.3389/fimmu.2026.2005289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 19.11.2026. Verfasst von Hiroyuki Tomita und 1 weiteren Autor:innen. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioma vaccines seek to direct immunity against malignant cells, including those dispersed beyond the tissue used to identify vaccine antigens. These infiltrative cells occupy neuronal, perivascular and white matter environments, where antigen expression, immune access and treatment sensitivity may differ from those in the tumor mass. In this narrative review, we examine how spatial tumor biology can guide antigen selection, vaccine platform choice, and the evaluation of antitumor immunity. We connect the pathology of diffuse invasion with evidence on neuron–glioma communication, histone mutations and glucose metabolism, tracing the steps from antigen expression to natural presentation and distinguishing systemic immunogenicity from recognition of residual cells. Histone-mutant gliomas illustrate a central difficulty: an oncogenic mutation may form a candidate antigen while shaping the tumor state in which immunity must act, yet evidence for vaccination differs across molecular entities. Studies of glucose transporter 1 similarly highlight the distinct metabolic requirements of malignant cells, myeloid cells, and effector lymphocytes. Against this background, we assess peptide, dendritic cell, nucleic acid, and viral vector approaches, with combinations designed to support immune priming or local effector function. We then propose preclinical and clinical evaluations that relate antigen coverage, presentation, and immune engagement to residual tumor control. The aim is to align vaccine design and evaluation with the biology of the infiltrative disease that remains after treatment.

Zitieren

APA

Tomita, H., & Hara, A. (2026). Vaccinating against infiltrative glioma: antigen selection, neuronal niches, and immune access. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.2005289

Vancouver

Tomita H, Hara A. Vaccinating against infiltrative glioma: antigen selection, neuronal niches, and immune access. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.2005289

BibTeX
@article{Tomita2026,
  author = {Tomita, Hiroyuki and Hara, Akira},
  title = {Vaccinating against infiltrative glioma: antigen selection, neuronal niches, and immune access},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.2005289}
}
Kostenlos starten →